Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.

Gao J, Zhou J, Li Y, Peng Z, Li Y, Wang X, Shen L.

Med Oncol. 2013;30(3):630. doi: 10.1007/s12032-013-0630-8. Epub 2013 Jun 20.

PMID:
23783485
2.

UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.

Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L.

Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x. Epub 2013 May 18.

PMID:
23686699
3.

Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.

Yang C, Liu Y, Xi WQ, Zhou CF, Jiang JL, Ma T, Ye ZB, Zhang J, Zhu ZG.

Drug Des Devel Ther. 2015 Jul 17;9:3677-83. doi: 10.2147/DDDT.S86750. eCollection 2015.

4.

Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.

Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Chamnanphon M, Puangpetch A, Wongwaisayawan S, Sukasem C.

Drug Metab Pharmacokinet. 2016 Feb;31(1):90-4. doi: 10.1016/j.dmpk.2015.12.004. Epub 2015 Dec 31.

PMID:
26830078
5.

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.

Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS.

Cancer. 2008 May 1;112(9):1932-40. doi: 10.1002/cncr.23370.

6.

UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.

Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY, Xu JM.

World J Gastroenterol. 2012 Dec 7;18(45):6635-44. doi: 10.3748/wjg.v18.i45.6635.

7.

Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.

Yan L, Wang XF, Wei LM, Nie YL, Liu JY, Zhang LR.

Int J Clin Pharmacol Ther. 2016 Mar;54(3):193-9. doi: 10.5414/CP202442.

PMID:
26857783
8.

Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.

Sai K, Saito Y, Sakamoto H, Shirao K, Kurose K, Saeki M, Ozawa S, Kaniwa N, Hirohashi S, Saijo N, Sawada J, Yoshida T.

Cancer Lett. 2008 Mar 18;261(2):165-71. Epub 2007 Dec 20.

PMID:
18082937
9.

UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.

Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M.

Cancer Sci. 2013 Dec;104(12):1662-9. doi: 10.1111/cas.12283. Epub 2013 Oct 27.

10.

UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.

Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL, Qian XP.

Cancer Chemother Pharmacol. 2014 Mar;73(3):551-60. doi: 10.1007/s00280-014-2382-3. Epub 2014 Jan 22. Review.

PMID:
24448639
11.

Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.

Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, Lv YL, Liu H, An GY, Liu LH.

Cancer Chemother Pharmacol. 2014 Apr;73(4):779-88. doi: 10.1007/s00280-014-2405-0. Epub 2014 Feb 12.

PMID:
24519753
12.

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K.

Int J Clin Oncol. 2009 Apr;14(2):136-42. doi: 10.1007/s10147-008-0821-z. Epub 2009 Apr 24.

PMID:
19390945
13.

Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.

Lu YY, Huang XE, Wu XY, Cao J, Liu J, Wang L, Xiang J.

Asian Pac J Cancer Prev. 2014;15(7):3335-41.

14.

Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.

Hirasawa A, Zama T, Akahane T, Nomura H, Kataoka F, Saito K, Okubo K, Tominaga E, Makita K, Susumu N, Kosaki K, Tanigawara Y, Aoki D.

J Hum Genet. 2013 Dec;58(12):794-8. doi: 10.1038/jhg.2013.105. Epub 2013 Oct 3. Erratum in: J Hum Genet. 2013 Dec;58(12):825.

PMID:
24088669
15.

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y.

Cancer Res. 2000 Dec 15;60(24):6921-6.

16.

The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.

Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, Frustaci S.

J Clin Oncol. 2006 Jul 1;24(19):3061-8.

PMID:
16809730
17.

[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].

Li H, Huang H, Liu JH.

Zhonghua Fu Chan Ke Za Zhi. 2011 Dec;46(12):888-91. Chinese.

PMID:
22333276
18.

Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.

Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY, Sharma MR.

World J Gastroenterol. 2013 Jun 28;19(24):3899-903. doi: 10.3748/wjg.v19.i24.3899.

19.

UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer.

Zhou CF, Ma T, Su Y, Ye ZB, Ji J, Yu YY, Zhang J, Liu BY, Zhu ZG.

Anticancer Agents Med Chem. 2013 Feb;13(2):235-41.

PMID:
22934695
20.

[Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].

Ma L, Chen Y, Yang C, Jiang H, Zhu J, Cheng Y.

Zhonghua Zhong Liu Za Zhi. 2015 Jan;37(1):29-32. Chinese.

PMID:
25877315

Supplemental Content

Support Center